PDS Biotechnology Corp.
NASDAQ: PDSB1 known investors
PDS Biotech develops targeted immunotherapies using its Versamune T cell activating platform and PDS01ADC technology to induce tumor-infiltrating T cell responses. The company focuses on cancer treatments and infectious disease vaccines that harness the immune system.
Investors Β· 1
Competitors Β· 6
by search overlap
StockTwits25 shared keywordsStocktwits operates an online community platform where investors and traders share ideas, analysis, and trade discussions organized around stock tickers. The page presented is its community guidelines rather than a product description.
Seeking Alpha23 shared keywordsSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
Robinhood23 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Simply Wall St22 shared keywordsSimply Wall St is a stock analysis platform that provides portfolio insights, stock discovery tools, and market alerts for individual investors. The service offers institutional-grade financial data visualization and analysis across 120,000 global stocks.
TradingView20 shared keywordsTradingView is a charting platform and social network used by over 100 million traders and investors worldwide to analyze and trade across global financial markets. The platform provides tools for technical analysis, market data, and community collaboration for retail and institutional traders.
Public18 shared keywordsPublic is a trading platform that allows users to buy and sell cryptocurrencies including Bitcoin, Ethereum, and memecoins through accounts managed by Zero Hash LLC, a New York State-licensed virtual currency business.
Companies competing with PDS Biotechnology Corp. for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding Β· 4 SBIR/STTR awards
Federal grants β no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2010 | $174.3K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2009 | $1.3M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2008 | $166.5K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2007 | $149.3K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts β non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does PDS Biotechnology Corp. do?
- PDS Biotech develops targeted immunotherapies using its Versamune T cell activating platform and PDS01ADC technology to induce tumor-infiltrating T cell responses. The company focuses on cancer treatments and infectious disease vaccines that harness the immune system.
- Who are PDS Biotechnology Corp.'s investors?
- PDS Biotechnology Corp.'s investors include Elevate Ventures.